{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:05:53Z","timestamp":1789675553061,"version":"4.0.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,8,1]],"date-time":"2016-08-01T00:00:00Z","timestamp":1470009600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","award":["R15 CA 173688"],"award-info":[{"award-number":["R15 CA 173688"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Rider University"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cellular Immunology"],"published-print":{"date-parts":[[2016,8]]},"DOI":"10.1016\/j.cellimm.2016.05.004","type":"journal-article","created":{"date-parts":[[2016,5,28]],"date-time":"2016-05-28T21:01:36Z","timestamp":1464469296000},"page":"17-24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["Erythropoietin increases macrophage-mediated T cell suppression"],"prefix":"10.1016","volume":"306-307","author":[{"given":"Michelle A.","family":"Wood","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Goldman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kelley","family":"DePierri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Somerville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James E.","family":"Riggs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cellimm.2016.05.004_b0005","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.coi.2014.01.004","article-title":"New insights into cancer immunoediting and its three component phases \u2013 elimination, equilibrium, escape","volume":"27","author":"Mittal","year":"2014","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.cellimm.2016.05.004_b0010","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1038\/nrc2444","article-title":"The role of myeloid cells in the promotion of tumor angiogenesis","volume":"8","author":"Murdoch","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cellimm.2016.05.004_b0015","first-page":"11","article-title":"Tumor-associated macrophages: effectors of angiogenesis and tumor progression","volume":"1796","author":"Coffelt","year":"2009","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.cellimm.2016.05.004_b0020","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1161\/01.ATV.17.11.2793","article-title":"Vascular endothelial growth factor\/vascular permeability factor produces nitric oxide-dependent hypotension. Evidence for a maintenance role in quiescent adult endothelium","volume":"17","author":"Horowitz","year":"1997","journal-title":"Arterioscler. Thromb. Vasc. Biol"},{"key":"10.1016\/j.cellimm.2016.05.004_b0025","first-page":"1650","article-title":"Tumors: wounds that do not heal-redux","volume":"315","author":"Dvorak","year":"2015","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.cellimm.2016.05.004_b0030","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1189\/jlb.0905495","article-title":"Monocyte\/macrophage infiltration in tumors: modulators of angiogenesis","volume":"80","author":"Dirkx","year":"2006","journal-title":"J. Leukoc. Biol."},{"key":"10.1016\/j.cellimm.2016.05.004_b0035","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.ccell.2015.02.015","article-title":"Macrophages and therapeutic resistance in cancer","volume":"27","author":"Ruffell","year":"2015","journal-title":"Cancer Cell"},{"key":"10.1016\/j.cellimm.2016.05.004_b0040","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1097\/PPO.0000000000000132","article-title":"Myeloid cells as targets for therapy in solid tumors","volume":"4","author":"Cotechini","year":"2015","journal-title":"J. Cancer"},{"key":"10.1016\/j.cellimm.2016.05.004_b0045","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/nrc2403","article-title":"VEGF-targeted therapy: mechanisms of anti-tumour activity","volume":"8","author":"Ellis","year":"2008","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cellimm.2016.05.004_b0050","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/bjc.1988.36","article-title":"Macrophages in human breast disease: a quantitative immunohistochemical study","volume":"57","author":"Kelly","year":"1988","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cellimm.2016.05.004_b0055","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1615\/CritRevImmunol.v21.i5.10","article-title":"Macrophage arginine metabolism to ornithine\/urea or nitric oxide\/citrulline: a life or death issue","volume":"21","author":"Mills","year":"2001","journal-title":"Crit. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2016.05.004_b0060","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1038\/nrc1256","article-title":"J, Tumor-educated macrophages promote tumor progression and metastasis","volume":"4","author":"Pollard","year":"2004","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.cellimm.2016.05.004_b0065","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1038\/nature07445","article-title":"Deletion of vascular endothelial growth factor in myeloid cells accelerates tumorigenesis","volume":"456","author":"Stockmann","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.cellimm.2016.05.004_b0070","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1182\/blood.V93.3.796","article-title":"Apoptotic role of Fas\/Fas ligand system in the regulation of erythropoiesis","volume":"93","author":"De Maria","year":"1999","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2016.05.004_b0075","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1182\/blood-2005-11-4458","article-title":"Suppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivo","volume":"108","author":"Liu","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2016.05.004_b0080","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.immuni.2011.01.002","article-title":"Erythropoietin contrastingly affects bacterial infection and experimental colitis by inhibiting nuclear factor-k-B-inducible immune pathways","volume":"34","author":"Nairz","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.cellimm.2016.05.004_b0085","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1056\/NEJM198701083160203","article-title":"Correction of the anemia of end-stage renal disease with recombinant human erythropoietin. Results of a combined phase I and II clinical trial","volume":"316","author":"Eschbach","year":"1987","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.cellimm.2016.05.004_b0090","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1200\/JCO.2006.08.8153","article-title":"Erythropoietin: high profile, high security","volume":"25","author":"Crawford","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.cellimm.2016.05.004_b0095","article-title":"Does erythropoietin have a dark side? Epo signaling and cancer cells","volume":"395","author":"Sytkowski","year":"2007","journal-title":"Sci. STKE"},{"key":"10.1016\/j.cellimm.2016.05.004_b0100","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.immuni.2011.01.004","article-title":"Erythropoietin surprises: an immune saga","volume":"34","author":"Broxmeyer","year":"2011","journal-title":"Immunity"},{"key":"10.1016\/j.cellimm.2016.05.004_b0105","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1097\/CCO.0b013e32833aa9de","article-title":"Erythropoietin in cancer patients: pros and cons","volume":"22","author":"Dicato","year":"2010","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.cellimm.2016.05.004_b0110","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.bjc.6605498","article-title":"Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes","volume":"102","author":"Glaspy","year":"2010","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.cellimm.2016.05.004_b0115","doi-asserted-by":"crossref","first-page":"4045","DOI":"10.1182\/blood-2010-08-300541","article-title":"American Society of Hematology\/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer","volume":"116","author":"Rizzo","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2016.05.004_b0120","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/scd.2009.0402","article-title":"Erythropoietin and tumor angiogenesis","volume":"19","author":"Ribatti","year":"2010","journal-title":"Stem Cells Dev."},{"key":"10.1016\/j.cellimm.2016.05.004_b0125","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1385\/IR:23:2-3:263","article-title":"VEGF as a mediator of tumor\u2013associated immunodeficiency","volume":"23","author":"Ohm","year":"2001","journal-title":"Immunol. Res."},{"key":"10.1016\/j.cellimm.2016.05.004_b0130","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/j.1365-2796.2008.02024.x","article-title":"Erythropoietin-mediated tissue protection: reducing collateral damage from the primary injury response","volume":"264","author":"Brines","year":"2008","journal-title":"J. Intern. Med."},{"key":"10.1016\/j.cellimm.2016.05.004_b0135","first-page":"3561","article-title":"Erythropoietin and erythropoietin receptor expression in human cancer","volume":"61","author":"Acs","year":"2001","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2016.05.004_b0140","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/ijc.23068","article-title":"Characterization of erythropoietin receptor and erythropoietin expression and function in human ovarian cancer cells","volume":"122","author":"Jeong","year":"2008","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.cellimm.2016.05.004_b0145","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.jim.2009.10.006","article-title":"Identification of a sensitive anti-erythropoietin receptor monoclonal antibody allows detection of low levels of EpoR in cells","volume":"352","author":"Elliott","year":"2009","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.cellimm.2016.05.004_b0150","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s00277-013-1947-2","article-title":"Progress in detecting cell-surface protein receptors: the erythropoietin receptor example","volume":"93","author":"Elliott","year":"2014","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.cellimm.2016.05.004_b0155","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.2353\/ajpath.2009.080592","article-title":"RNA interference-mediated inhibition of erythropoietin receptor expression suppresses tumor growth and invasiveness in A2780 ovarian carcinoma cells","volume":"174","author":"Paragh","year":"2009","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cellimm.2016.05.004_b0160","doi-asserted-by":"crossref","first-page":"4151","DOI":"10.1182\/blood-2010-03-271395","article-title":"Erythropoietin: back to basics","volume":"115","author":"Jelkmann","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2016.05.004_b0165","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.1182\/blood-2009-10-248666","article-title":"Functional erythropoietin receptor is undetectable in endothelial, cardiac, neuronal, and renal cells","volume":"115","author":"Sinclair","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2016.05.004_b0170","doi-asserted-by":"crossref","first-page":"4254","DOI":"10.1182\/blood-2009-10-248674","article-title":"Absence of functional EpoR expression in human tumor cell lines","volume":"115","author":"Swift","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2016.05.004_b0175","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/bjh.13133","article-title":"Novel antibodies directed against the human erythropoietin receptor: creating a basis for clinical implementation","volume":"168","author":"Maxwell","year":"2015","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.cellimm.2016.05.004_b0180","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1016\/j.exphem.2008.07.010","article-title":"Erythropoietin effects on dendritic cells: potential mediators in its function as an immunomodulator?","volume":"36","author":"Prutchi Sagiv","year":"2008","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.cellimm.2016.05.004_b0185","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.molimm.2008.10.004","article-title":"Non-erythroid activities of erythropoietin: functional effects on murine dendritic cells","volume":"46","author":"Lifshitz","year":"2010","journal-title":"Mol. Immunol."},{"key":"10.1016\/j.cellimm.2016.05.004_b0190","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.3324\/haematol.2010.025015","article-title":"Macrophages as novel targets for erythropoietin","volume":"95","author":"Lifshitz","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.cellimm.2016.05.004_b0195","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1111\/j.1525-1594.2009.00948.x","article-title":"Erythropoietin receptor is expressed on human peripheral blood T and B lymphocytes and monocytes and is modulated by recombinant human erythropoietin treatment","volume":"34","author":"Lisowska","year":"2010","journal-title":"Artif. Organs"},{"key":"10.1016\/j.cellimm.2016.05.004_b0200","doi-asserted-by":"crossref","first-page":"e12","DOI":"10.3324\/haematol.2010.038414","article-title":"Erythropoietin receptor is detectable on peripheral blood lymphocytes and its expression increases in activated T lymphocytes","volume":"96","author":"Lisowska","year":"2011","journal-title":"Haematologica"},{"key":"10.1016\/j.cellimm.2016.05.004_b0205","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/j.1365-2567.2005.02312.x","article-title":"Peritoneal macrophages suppress T-cell activation by amino acid catabolism","volume":"117","author":"Matlack","year":"2006","journal-title":"Immunology"},{"key":"10.1016\/j.cellimm.2016.05.004_b0210","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.imbio.2010.04.002","article-title":"Peritoneal T lymphocyte regulation by macrophages","volume":"216","author":"Composto","year":"2011","journal-title":"Immunobiology"},{"key":"10.1016\/j.cellimm.2016.05.004_b0215","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.imbio.2009.01.015","article-title":"Cytokine treatment of macrophage suppression of T cell activation","volume":"215","author":"Silberman","year":"2010","journal-title":"Immunobiology"},{"key":"10.1016\/j.cellimm.2016.05.004_b0220","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1038\/cmi.2012.13","article-title":"CD28 ligation increases macrophage suppression of T-cell proliferation","volume":"9","author":"Silberman","year":"2012","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.cellimm.2016.05.004_b0225","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/nri3064","article-title":"The parallel lives of angiogenesis and immunosuppression: cancer and other tales","volume":"11","author":"Motz","year":"2011","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.cellimm.2016.05.004_b0230","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/S1471-4906(03)00072-3","article-title":"Tolerance, DCs and tryptophan: much ado about IDO","volume":"24","author":"Grohmann","year":"2003","journal-title":"Trends Immunol."},{"key":"10.1016\/j.cellimm.2016.05.004_b0235","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1111\/j.1365-2249.2011.04417.x","article-title":"Erythropoietin enhances immunostimulatory properties of immature dendritic cells","volume":"165","author":"Rocchetta","year":"2011","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.cellimm.2016.05.004_b0240","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1681\/ASN.2013090945","article-title":"Immunosuppressive effects of erythropoietin on human alloreactive T cells","volume":"25","author":"Cravedi","year":"2014","journal-title":"J. Am. Soc. Nephrol."},{"key":"10.1016\/j.cellimm.2016.05.004_b0245","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1093\/jimmunol\/175.1.5","article-title":"Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. 1986","volume":"175","author":"Mosmann","year":"2005","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.05.004_b0250","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/S0022-1759(00)00156-3","article-title":"Superoxide produced by activated neutrophils efficiently reduces the tetrazolium salt, WST-1 to produce a soluble formazan: a simple colorimetric assay for measuring respiratory burst activation and for screening anti-inflammatory agents","volume":"238","author":"Tan","year":"2000","journal-title":"J. Immunol. Methods"},{"key":"10.1016\/j.cellimm.2016.05.004_b0255","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S1387-2656(05)11004-7","article-title":"Tetrazolium dyes as tools in cell biology: new insights into their cellular reduction","volume":"11","author":"Berridge","year":"2005","journal-title":"Biotechnol. Annu. Rev."},{"key":"10.1016\/j.cellimm.2016.05.004_b0260","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1016\/S0002-9440(10)63459-1","article-title":"A novel role for erythropoietin during fibrin-induced wound-healing response","volume":"163","author":"Haroon","year":"2003","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.cellimm.2016.05.004_b0265","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.micinf.2011.10.005","article-title":"The pleiotropic effects of erythropoietin in infection and inflammation","volume":"14","author":"Nairz","year":"2012","journal-title":"Microbes Infect."},{"key":"10.1016\/j.cellimm.2016.05.004_b0270","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2009-04-216432","article-title":"Induction of nitric oxide by erythropoietin is mediated by the beta common receptor and requires interaction with the VEGF receptor 2","volume":"115","author":"Sautina","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2016.05.004_b0275","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.cyto.2011.01.015","article-title":"Erythropoietin and hypoxia increase erythropoietin receptor and nitric oxide levels in lung microvascular endothelial cells","volume":"54","author":"Beleslin-Cokic","year":"2011","journal-title":"Cytokine"},{"key":"10.1016\/j.cellimm.2016.05.004_b0280","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.4049\/jimmunol.180.4.2011","article-title":"Plasticity of macrophage function during tumor progression: regulation by distinct molecular mechanisms","volume":"180","author":"Biswas","year":"2008","journal-title":"J. Immunol."},{"key":"10.1016\/j.cellimm.2016.05.004_b0285","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1097-2765(01)00401-4","article-title":"The N-terminal domain of Janus kinase 2 is required for Golgi processing and cell surface expression of erythropoietin receptor","volume":"8","author":"Huang","year":"2001","journal-title":"Mol. Cell"},{"issue":"90","key":"10.1016\/j.cellimm.2016.05.004_b0290","doi-asserted-by":"crossref","first-page":"1867","DOI":"10.1182\/blood.V90.5.1867","article-title":"The beta chain of the interleukin-3 receptor functionally associates with the erythropoietin receptor","volume":"1997","author":"Jubinsky","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.cellimm.2016.05.004_b0295","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1084\/jem.20122760","article-title":"Erythropoietin: multiple targets, actions, and modifying influences for biological and clinical consideration","volume":"210","author":"Broxmeyer","year":"2013","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.cellimm.2016.05.004_b0300","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1113\/jphysiol.2010.195057","article-title":"Regulation of erythropoietin production","volume":"589","author":"Jelkman","year":"2011","journal-title":"J. Physiol."},{"issue":"2011","key":"10.1016\/j.cellimm.2016.05.004_b0305","first-page":"480","article-title":"Performance characteristics of a new Immulite (\u00ae) 2000 system erythropoietin assay System erythropoietin assay","volume":"412","author":"Owen","year":"2000","journal-title":"Clin. Chim. Acta"},{"key":"10.1016\/j.cellimm.2016.05.004_b0310","unstructured":"<http:\/\/assets.procrit.com\/shared\/product\/procrit\/procrit-prescribing-information.pdf>."},{"key":"10.1016\/j.cellimm.2016.05.004_b0315","doi-asserted-by":"crossref","first-page":"4506","DOI":"10.1158\/0008-5472.CAN-10-3787","article-title":"Erythropoietin induces lymph node lymphangiogenesis and lymph node tumor metastasis","volume":"71","author":"Lee","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.cellimm.2016.05.004_b0320","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1593\/neo.08140","article-title":"Erythropoietin promotes the growth of tumors lacking its receptor and decreases survival of tumor-bearing mice by enhancing angiogenesis","volume":"10","author":"Okazaki","year":"2008","journal-title":"Neoplasia"},{"key":"10.1016\/j.cellimm.2016.05.004_b0325","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1006\/bbrc.1997.6323","article-title":"Inducible nitric oxide synthase expression and erythropoietin production in human hepatocellular carcinoma cells","volume":"232","author":"Yoshioka","year":"1997","journal-title":"Biochem. Biophys. Res. Commun."}],"container-title":["Cellular Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874916300363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008874916300363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T22:54:11Z","timestamp":1757804051000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008874916300363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8]]},"references-count":65,"alternative-id":["S0008874916300363"],"URL":"https:\/\/doi.org\/10.1016\/j.cellimm.2016.05.004","relation":{},"ISSN":["0008-8749"],"issn-type":[{"value":"0008-8749","type":"print"}],"subject":[],"published":{"date-parts":[[2016,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Erythropoietin increases macrophage-mediated T cell suppression","name":"articletitle","label":"Article Title"},{"value":"Cellular Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cellimm.2016.05.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}